Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
12 hedge funds and large institutions have $16.5M invested in Anebulo Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
0.76% more ownership
Funds ownership: 26.67% → 27.44% (+0.76%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
17% less capital invested
Capital invested by funds: $19.8M → $16.5M (-$3.34M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
+$449K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.48K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$120 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$2.5K |
| 2 |
BlackRock
New York
|
-$699 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $11.9M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.58M | -$2.5K | -1,000 | -0.1% |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.2M | – | – | – |
|
|
MP
4
Mangrove Partners
Greenwich,
Connecticut
| $938K | – | – | – |
|
|
PP
5
Praetorian PR
Rincon,
Puerto Rico
| $423K | +$449K | +180,005 | New |
|
|
IC
6
Ikarian Capital
Dallas,
Texas
| $341K | – | – | – |
|
|
BFM
7
Boothbay Fund Management
New York
| $40.7K | – | – | – |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| $37.7K | +$40K | +16,032 | New |
|
|
9
BlackRock
New York
| $17K | -$699 | -280 | -4% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $14.3K | +$2.48K | +994 | +19% |
|
|
11
Wells Fargo
San Francisco,
California
| $134 | +$5 | +2 | +4% |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$120 | +48 | New |
|
ANEB Hedge Fund Activity: Q2 2023 in Review
12 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q2 2023, worth a combined $16.5M — down 17% from $19.8M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANEB positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Praetorian PR, opening a new position worth an estimated $449K. The largest seller was LVW Advisors, cutting an estimated $2.5K.
- 12 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q2 2023, up from 10 in Q1 2023.
- Funds reported $16.5M of Anebulo Pharmaceuticals stock for Q2 2023, down 17% quarter-over-quarter.
- 3 funds opened new Anebulo Pharmaceuticals positions in Q2 2023 and 1 closed out, a net change of +2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q2 2023 was Praetorian PR, an estimated $449K added.
- The largest Anebulo Pharmaceuticals seller in Q2 2023 was LVW Advisors, an estimated $2.5K sold.
Based on aggregated 13F filings for Q2 2023.